Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 937-947 , October 2008

Musculoskeletal complications encountered in the lysosomal storage disorders

  • Gregory M. Pastores, MD (Associate Professor of Neurology and Pediatrics)

      Affiliations

    • Corresponding Author Information403 East 34th Street, 2nd floor, New York, NY 10016, USA. Tel.: +212 263 8344; Fax: +212 263 8310.

References 

  1. Vellodi A. Lysosomal storage disorders. British Journal of Haematology. 2005;128(4):413–431
  2. Blocklet D, Abramowicz M, Schoutens A. Bone, bone marrow, and MIBI scintigraphic findings in Gaucher's disease ‘bone crisis’. Clinical Nuclear Medicine. 2001;26(9):765–769
  3. Maas M, Hangartner T, Mariani G, et al. Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Skeletal Radiology. 2008;37(3):185–188
  4. Maas M, Hollak CE, Akkerman EM, et al. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR. American Journal of Roentgenology. 2002;179(4):961–965
  5. Vlieger EJ, Maas M, Akkerman EM, et al. Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease. Journal of Computer Assisted Tomography. 2002;26(5):843–848
  6. Mersebach H, Johansson JO, Rasmussen AK, et al. Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genetics in Medicine. 2007;9(12):812–818
  7. Yoshino M, Watanabe Y, Tokunaga Y, et al. Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease. Pediatrics International. 2007;49(6):959–965
  8. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. The Journal of Pediatrics. 2004;144(5 Suppl):S27–S34
  9. Yuen A, Dowling G, Johnstone B, et al. Carpal tunnel syndrome in children with mucopolysaccaridoses. Journal of Child Neurology. 2007;22(3):260–263
  10. Cimaz R, Vijay S, Haase C, et al. Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome. Clinical and Experimental Rheumatology. 2006;24(2):196–202
  11. Pizzutillo PD, Osterkamp JA, Scott CI, Lee MS. Atlantoaxial instability in mucopolysaccharidosis type VII. Journal of Pediatric Orthopedics. 1989;9(1):76–78
  12. Paulson GW, Meagher JN, Burkhart J. Spinal pachymeningitis secondary to mucopolysaccharidosis. Case report. Journal of Neurosurgery. 1974;41(5):618–621
  13. Belani KG, Krivit W, Carpenter BL, et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. Journal of Pediatric Surgery. 1993;28(3):403–408
  14. Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Laboratory Investigation; A Journal of Technical Methods and Pathology. 2001;81:1319–1328
  15. Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatric Research. 2005;57:701–707
  16. Simonaro CM, D'Angelo M, He X, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. The American Journal of Pathology. 2008;172(1):112–122
  17. Pastores GM, Barnett NL. Current and emerging therapies for the lysosomal storage disorders. Expert Opinion on Emerging Drugs. 2005;10(4):891–902
  18. Fan JQ, Ishii S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. The FEBS Journal. 2007;274(19):4962–4971
  19. Malm G, Gustafsson B, Berglund G, et al. Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT). Acta Paediatrica. 2008;
  20. Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Molecular Genetics and Metabolism. 2007;90(2):171–180
  21. Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120(1):e37–e46
  22. Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Molecular Genetics and Metabolism. 2007;91(1):61–68
  23. Coman DJ, Hayes IM, Collins V, et al. Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families. The Journal of Pediatrics. 2008;152(5):723–727
  24. Schmitz J, Poll LW, vom Dahl S. Therapy of adult Gaucher disease. Haematologica. 2007;92(2):148–152
  25. Charrow J, Dulisse B, Grabowski GA, et al. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clinical Genetics. 2007;71(3):205–211
  26. Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clinical Genetics. 2008;73(5):430–440
  27. Weinreb N, Barranger J, Packman S, et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clinical Genetics. 2007;71(6):576–588
  28. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). The Journal of Pediatrics. 2004;144(5):581–588
  29. Starzyk K, Richards S, Yee J, et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Molecular Genetics and Metabolism. 2007;90(2):157–163
  30. Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood. 2004;104(5):1253–1257
  31. Pastores GM, Elstein D, Hrebícek M, et al. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clinical Therapeutics. 2007;29(8):1645–1654
  32. Case LE, Hanna R, Frush DP, et al. Fractures in children with Pompe disease: a potential long-term complication. Pediatric Radiology. 2007;37(5):437–445
  33. Connock M, Burls A, Frew E, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technology Assessment (Winchester, England). 2006;10(24):iii–iivix–136
  34. Connock M, Juarez-Garcia A, Frew E, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technology Assessment (Winchester, England). 2006;10(20):iii–iivix–113
  35. Moore DF, Ries M, Forget EL, Schiffmann R. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease. Pharmacoeconomics. 2007;25(3):201–208
  36. Lebel E, Itzchaki M, Hadas-Halpern I, et al. Outcome of total hip arthroplasty in patients with Gaucher disease. The Journal of Arthroplasty. 2001;16(1):7–12
  37. George MD, Pearse MF. Cemented revision total hip arthroplasty with impaction bone grafting in Gaucher's disease. The Journal of Arthroplasty. 2002;17(5):667–669
  38. Matern D. Newborn screening for lysosomal storage disorders. Acta Paediatrica (Oslo, Norway: 1992). Supplement. 2008 Apr;97(457):33–37

PII: S1521-6942(08)00100-9

doi: 10.1016/j.berh.2008.09.005

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 937-947 , October 2008

Article Tools

* Image Usage & Resolution